ébé. Ces résultats <strong>de</strong> la recherche biomédica<strong>le</strong> <strong>de</strong>vront être intégrés à la pratique clinique selon <strong>le</strong> principed’une pratique médica<strong>le</strong> fondée sur <strong>de</strong>s données probantes.RÉFÉRENCES1. Eng<strong>le</strong>, W.A., Age terminology during the perinatal period. Pediatrics, 2004. 114(5): p. 1362-4.2. Les indicateurs <strong>de</strong> la santé périnata<strong>le</strong> au Canada : Manuel <strong>de</strong> référencePublished by authority of the Minister of Health, 2000.3. Joseph, K.S., et al., Determinants of preterm birth rates in Canada from 1981 through 1983 and from 1992through 1994. N Engl J Med, 1998. 339(20): p. 1434-9.4. Ministère <strong>de</strong> la Santé et <strong>de</strong>s Services Sociaux du Québec, 2002.5. Moss, T.J., Respiratory consequences of preterm birth. Clin Exp Pharmacol Physiol, 2006. 33(3): p. 280-4.6. Jaubert, J., J. Cheng, and J.A. Segre, Ectopic expression of kruppel like factor 4 (Klf4) acce<strong>le</strong>rates formation ofthe epi<strong>de</strong>rmal permeability barrier. Development, 2003. 130(12): p. 2767-77.7. Furuse, M., et al., Claudin-based tight junctions are crucial for the mammalian epi<strong>de</strong>rmal barrier: a <strong>le</strong>ssonfrom claudin-1-<strong>de</strong>ficient mice. J Cell Biol, 2002. 156(6): p. 1099-111.8. Turksen, K. and T.C. Troy, Permeability barrier dysfunction in transgenic mice overexpressing claudin 6.Development, 2002. 129(7): p. 1775-84.9. Han<strong>le</strong>y, J.M., J.L. Pierce, and W.F. Gayton, Positive attitu<strong>de</strong>s towards suntanning and reported ten<strong>de</strong>ncy toengage in lifesty<strong>le</strong> behaviors that increase risk of skin cancer. Psychol Rep, 1996. 79(2): p. 417-8.10. Van Overmeire, B. and S. Chemtob, The pharmacologic closure of the patent ductus arteriosus. Semin FetalNeonatal Med, 2005. 10(2): p. 177-84.11. Hunter, C.J., et al., Un<strong>de</strong>rstanding the susceptibility of the premature infant to necrotizing enterocolitis(NEC). Pediatr Res, 2008. 63(2): p. 117-23.12. McMurtry, I.F., Introduction: pre- and postnatal lung <strong>de</strong>velopment, maturation, and plasticity. Am J PhysiolLung Cell Mol Physiol, 2002. 282(3): p. L341-4.13. Copland, I. and M. Post, Lung <strong>de</strong>velopment and fetal lung growth. Paediatr Respir Rev, 2004. 5 Suppl A: p.S259-64.14. Costa, R.H., V.V. Kalinichenko, and L. Lim, Transcription factors in mouse lung <strong>de</strong>velopment and function.Am J Physiol Lung Cell Mol Physiol, 2001. 280(5): p. L823-38.15. Warburton, D., et al., The mo<strong>le</strong>cular basis of lung morphogenesis. Mech Dev, 2000. 92(1): p. 55-81.49
16. Derin, B.G., et al., Immunohistochemical localization of extracellular matrix proteins in <strong>de</strong>veloping lungtissues. Saudi Med J, 2007. 28(3): p. 334-8.17. Reponen, P., et al., Mo<strong>le</strong>cular cloning of murine 72-kDa type IV collagenase and its expression duringmouse <strong>de</strong>velopment. J Biol Chem, 1992. 267(11): p. 7856-62.18. Fukuda, Y., et al., Matrix metalloproteinases and tissue inhibitor of metalloproteinase-2 in fetal rabbit lung.Am J Physiol Lung Cell Mol Physiol, 2000. 279(3): p. L555-61.19. Rolland, G., et al., Expression and characterization of type IV collagenases in rat lung cells during<strong>de</strong>velopment. Exp Cell Res, 1995. 218(1): p. 346-50.20. Mil<strong>le</strong>r, T.L., et al., Expression of matrix metalloproteinases 2, 7 and 9, and their tissue inhibitors 1 and 2, in<strong>de</strong>veloping rabbit tracheae. Biol Neonate, 2006. 89(4): p. 236-43.21. Gill, S.E., et al., A null mutation for tissue inhibitor of metalloproteinases-3 (Timp-3) impairs murinebronchio<strong>le</strong> branching morphogenesis. Dev Biol, 2003. 261(2): p. 313-23.22. Masumoto, K., et al., Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinasesduring normal human pulmonary <strong>de</strong>velopment. Histopathology, 2005. 47(4): p. 410-9.23. O'Connor, C.M. and M.X. FitzGerald, Matrix metalloproteases and lung disease. Thorax, 1994. 49(6): p. 602-9.24. Stevenson, D.K., et al., Very low birth weight outcomes of the National Institute of Child Health and HumanDevelopment Neonatal Research Network, January 1993 through December 1994. Am J Obstet Gynecol, 1998.179(6 Pt 1): p. 1632-9.25. Farrell, P.M. and M.E. Avery, Hyaline membrane disease. Am Rev Respir Dis, 1975. 111(5): p. 657-88.26. Dani, C., et al., Risk factors for the <strong>de</strong>velopment of respiratory distress syndrome and transient tachypnoeain newborn infants. Italian Group of Neonatal Pneumology. Eur Respir J, 1999. 14(1): p. 155-9.27. Rodriguez, R.J., Management of respiratory distress syndrome: an update. Respir Care, 2003. 48(3): p. 279-86; discussion 286-7.28. Lankenau, H.M., A genetic and statistical study of the respiratory distress syndrome. Eur J Pediatr, 1976.123(3): p. 167-77.29. Floros, J., et al., Dinuc<strong>le</strong>oti<strong>de</strong> repeats in the human surfactant protein-B gene and respiratory-distresssyndrome. Biochem J, 1995. 305 ( Pt 2): p. 583-90.30. Kala, P., et al., Association of pulmonary surfactant protein A (SP-A) gene and respiratory distresssyndrome: interaction with SP-B. Pediatr Res, 1998. 43(2): p. 169-77.31. Hamvas, A., et al., Surfactant protein B <strong>de</strong>ficiency: antenatal diagnosis and prospective treatment withsurfactant replacement. J Pediatr, 1994. 125(3): p. 356-61.50
- Page 7 and 8: REMERCIEMENTSBien que leurs noms ne
- Page 9 and 10: INTRODUCTIONAu cours des dernières
- Page 11 and 12: L’influence de la prématurité e
- Page 13 and 14: INTRODUCTIONL’accouchement préma
- Page 15 and 16: Tableau 2Statistiques de survie des
- Page 17 and 18: indiquent que l’obésité réduir
- Page 19 and 20: Tableau 5Percentiles des poids (g)
- Page 21 and 22: détresse respiratoire que les peti
- Page 23 and 24: confirmée par plusieurs autres ess
- Page 25 and 26: Références1. Reed DM, Stanley FJ:
- Page 27 and 28: 32. Honest H, Bachmann LM, Ngai C,
- Page 29 and 30: L’influence de la prématurité e
- Page 31 and 32: laboratoire du Dr Yves Tremblay. El
- Page 33 and 34: Introductionlusieurs paramètres pe
- Page 35 and 36: Le canal artériel crée une joncti
- Page 37 and 38: Figure 1. Histologie du poumon de s
- Page 39 and 40: cette variation allélique. D’aut
- Page 41 and 42: Chez le rat, la DHT réduit, dans d
- Page 43 and 44: les mécanismes subtils de la matur
- Page 45 and 46: Signaux de communication entre le m
- Page 47 and 48: FONDEMENTS BIOMÉDICAUX DES THÉRAP
- Page 49: L’OCCLUSION TRACHÉALECette techn
- Page 53 and 54: 49. Nielsen, H.C., H.M. Zinman, and
- Page 55 and 56: 80. Bahasadri, S. and N. Changizi,
- Page 57 and 58: 111. Tremblay, L.O., et al., Respir
- Page 59 and 60: L’influence de la prématurité e
- Page 61 and 62: INTRODUCTIONAlors que les médias n
- Page 63 and 64: scolaire professionnelle et ils ont
- Page 65 and 66: l’âge de 6 ans présenteraient a
- Page 67 and 68: S’il s’agit en plus d'un enfant
- Page 69 and 70: RÉFÉRENCES1. O'Shea TM, Kuban KC,
- Page 71 and 72: 31. Garel M, Bahuaud M, Blondel B:
- Page 73 and 74: PRÉSENTATION DE L'AUTEUREMireille
- Page 75 and 76: non) et selon les décisions prises
- Page 77 and 78: L’ÊTRE HUMAIN ET LA SÉLECTION N
- Page 79 and 80: pratiques aient évolué depuis ce
- Page 81 and 82: survivants soient disponibles, des
- Page 83 and 84: de certitude scientifique sur les r
- Page 85 and 86: LA PLACE DES PARENTSPlusieurs group
- Page 87 and 88: l’équipe soignante. Dans ces mom
- Page 89 and 90: ANNEXE 1Définitions de concepts cl
- Page 91 and 92: 17. Chervenak, F. A., McCullough, L
- Page 93 and 94: REMERCIEMENTS DE LA PART DE L'AUTEU
- Page 95 and 96: INTRODUCTIONÀ mesure que les progr
- Page 97 and 98: dans l’affaire Tremblay c. Daigle
- Page 99 and 100: La viabilité est conditionnelle à
- Page 101 and 102:
consentement aux soins du prématur
- Page 103 and 104:
libre et éclairé 52 ;Nul ne peut
- Page 105 and 106:
sont uniques selon son âge et sa c
- Page 107 and 108:
18 Tremblay c. Daigle, [1989] 2 R.C
- Page 109 and 110:
45 Robert P.KOURI, Suzanne PHILIPS-
- Page 111 and 112:
L’influence de la prématurité e
- Page 113 and 114:
critères de nature clinique et ép
- Page 115 and 116:
qualité de vie acceptable. Ainsi,
- Page 117 and 118:
RÉFÉRENCESOuvrages générauxVers